Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Ploner, F; Jakesz, R; Hausmaninger, H; Kolb, R; Stierer, M; Fridrik, M; Steindorfer, P; Gnant, M; Haider, K; Mlineritsch, B; Tschurtschenthaler, G; Steger, G; Seifert, M; Kubista, E; Samonigg, H; Austrian Breast And Colorectal Cancer Study Group.
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
Onkologie. 2003; 26(2):115-119
Doi: 10.1159/000069831
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Ploner Ferdinand
- Co-Autor*innen der Med Uni Graz
- Hofmann Guenter
- Samonigg Hellmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- AIM: A randomised, controlled clinical trial was initiated in 1984 to test whether 1 cycle of anthracycline-containing adjuvant chemotherapy improves the outcome of breast cancer patients presenting with stage II disease and negative oestrogen and progesterone receptors (ER, PgR), as compared with 6 cycles of dose-reduced CMF. PATIENTS AND METHODS: Within 7 years 263 women with stage II breast cancer were randomised either to receive 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5- fluorouracil (AV-CMF) or to receive 6 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Patients were stratified for tumour stage, nodal stage, menopausal status, type of surgery and participating centre. RESULTS: After a median follow-up of 100 months, neither disease-free (DFS) nor overall survival (OS) differed significantly between the two groups. CONCLUSIONS: Compared to 6 cycles of a non-standard low-dose CMF regimen 1 cycle of anthracycline- containing adjuvant chemotherapy failed to improve the outcome in women with stage II receptor-negative breast cancer in terms of DFS and OS.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Combined Chemotherapy Protocols - adverse effects
- Breast Neoplasms - drug therapy
- Carcinoma, Ductal, Breast - drug therapy
- Carcinoma, Lobular - drug therapy
- Chemotherapy, Adjuvant - drug therapy
- Cisplatin - adverse effects
- Combined Modality Therapy - adverse effects
- Cyclophosphamide - adverse effects
- Disease-Free Survival - adverse effects
- Dose-Response Relationship, Drug - adverse effects
- Doxorubicin - adverse effects
- Drug Administration Schedule - adverse effects
- Female - adverse effects
- Fluorouracil - adverse effects
- Humans - adverse effects
- Lymphatic Metastasis - adverse effects
- Methotrexate - adverse effects
- Middle Aged - adverse effects
- Neoplasm Staging - adverse effects
- Receptors, Estrogen - analysis
- Receptors, Progesterone - analysis
- Survival Rate - analysis
- Vincristine - adverse effects
- Find related publications in this database (Keywords)
- breast cancer
- chemotherapy
- adjuvant therapy